US Patent 11433100 Compositions and methods for treating ceacam positive cancers
Patent 11433100 was granted and assigned to A2 Biotherapeutics, Inc on September, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Carl Alexander Kamb0
Dora Toledo Warshaviak0
Han Xu0
Mark L. Sandberg0
Xueyin Wang0
Edits on 4 Apr, 2023
Golden AI
Edits on 28 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 26 Sep, 2022
Golden AI
Edits on 23 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 7 Sep, 2022
Golden AI
Edits made to:
Infobox (+19 properties)
Article (+191 characters)
US Patent 11433100 Compositions and methods for treating ceacam positive cancers
Article
The disclosure provides immune cells comprising a first activator receptor specific to CEA, and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
11433100
Date of Patent
September 6, 2022
Patent Application Number
17517559
Date Filed
November 2, 2021
Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11433100 Compositions and methods for treating ceacam positive cancers
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.